Francis M Giardiello Selected Research

Sulindac (Copal)

1/2017	Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
10/2005	Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
7/2005	Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
12/2004	Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
2/2004	Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
7/2003	Chemoprevention strategies using NSAIDs and COX-2 inhibitors.
7/2002	Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients.
4/2002	Primary chemoprevention of familial adenomatous polyposis with sulindac.
3/2002	Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francis M Giardiello Research Topics

Disease

19	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2020 - 03/2002
16	Polyps 01/2020 - 03/2002
15	Adenoma (Adenomas) 01/2018 - 03/2002
12	Neoplasms (Cancer) 01/2018 - 03/2003
12	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 01/2003
6	Carcinoma (Carcinomatosis) 01/2018 - 07/2003
5	Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal) 01/2018 - 06/2004
4	Adenomatous Polyps 01/2020 - 12/2004
3	Hemorrhage 01/2022 - 01/2022
3	Gastric Polyposis 01/2022 - 01/2022
3	Carcinogenesis 01/2018 - 03/2008
3	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2018 - 07/2005
2	Hamartoma 01/2018 - 08/2003
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2018 - 02/2015
2	Adenocarcinoma 12/2014 - 03/2008
2	Microsatellite Instability 10/2005 - 08/2003
1	Cognitive Dysfunction 01/2020
1	Kidney Neoplasms (Kidney Cancer) 01/2018
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Leukemia 01/2018
1	Overweight 04/2014
1	Inflammation (Inflammations) 04/2014
1	Genetic Predisposition to Disease (Genetic Predisposition) 06/2012
1	Enterocolitis 04/2010
1	Juvenile polyposis syndrome 01/2009
1	Aberrant Crypt Foci 06/2008
1	Infections 01/2008
1	Primary Immunodeficiency Diseases 01/2008
1	Bruton type agammaglobulinemia 01/2008
1	Eosinophilia 04/2007
1	Metaplasia 04/2007
1	Nasal Polyps (Nasal Polyp) 04/2007

Drug/Important Bio-Agent (IBA)

9	Sulindac (Copal)FDA LinkGeneric 01/2017 - 03/2002
6	Pharmaceutical PreparationsIBA 01/2017 - 03/2002
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2008
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2009 - 08/2003
4	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 06/2012 - 06/2004
4	beta CateninIBA 08/2010 - 08/2003
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 08/2006 - 07/2003
3	CurcuminIBA 01/2018 - 08/2006
3	Biomarkers (Surrogate Marker)IBA 06/2008 - 04/2004
3	ProstaglandinsIBA 04/2005 - 04/2002
2	PolyaminesIBA 01/2018 - 02/2004
2	Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA 01/2018 - 02/2004
2	Calcibiotic Root Canal SealerIBA 01/2018 - 10/2005
2	DNA (Deoxyribonucleic Acid)IBA 08/2015 - 08/2003
2	Celecoxib (Celebrex)FDA Link 06/2008 - 07/2003
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 04/2007 - 08/2003
2	4,6-dinitro-o-cresol (DNOC)IBA 10/2005 - 12/2004
2	Mixed Function Oxygenases (Monooxygenases)IBA 10/2005 - 12/2004
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 07/2005 - 03/2003
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 12/2004 - 07/2003
1	N-(3,4,5-trichlorophenyl)succinimideIBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	CarcinogensIBA 01/2018
1	Epithelial Cell Adhesion MoleculeIBA 01/2016
1	acceleratory factor from growth hormone (AcG)IBA 02/2015
1	C-Reactive ProteinIBA 04/2014
1	Eosine Yellowish-(YS) (Eosin)IBA 04/2011
1	Hematoxylin (Haematoxylon)IBA 04/2011
1	Codon (Codons)IBA 08/2010
1	Infliximab (Remicade)FDA Link 04/2010
1	Adalimumab (Humira)FDA Link 04/2010
1	Tumor Necrosis Factor InhibitorsIBA 04/2010
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010
1	AntigensIBA 01/2009
1	Estrogen Receptor alphaIBA 06/2008
1	Immunoglobulins (Immunoglobulin)IBA 01/2008
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2008
1	QuercetinIBA 08/2006
1	Melanins (Melanin)IBA 04/2006
1	Melanocyte-Stimulating Hormones (MSH)IBA 10/2005
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 10/2005
1	dimethylaniline monooxygenase (N-oxide forming) (flavin-containing monooxygenase)IBA 10/2005
1	Progesterone FDA LinkGeneric 04/2005
1	Hormones (Hormone)IBA 04/2005
1	Oral ContraceptivesIBA 04/2005
1	Estrogens (Estrogen)FDA Link 04/2005
1	Insulin (Novolin)FDA Link 04/2004
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2004
1	ParaffinIBA 08/2003
1	Cyclin D1IBA 08/2003
1	MucinsIBA 03/2003

Therapy/Procedure

8	Chemoprevention 01/2018 - 04/2002
7	Colectomy 01/2018 - 03/2002
5	Therapeutics 01/2018 - 03/2002
1	Oral Administration 01/2018
1	Drug Therapy (Chemotherapy) 01/2018
1	Gastrectomy 12/2014